Search our scientific publications and resources
on rare bleeding disorders
Scientific resources from Novo Nordisk
Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.
We found 383 resources matching your search criteria
Shapiro A, Castaman G, Cepo K, Tønder SM, Matsushita T, Poulsen LH, Young G, Zupancic-Šalek S, Jiménez Yuste V. Safety and Longer-term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Haemophilia. 2021;27(S2): 128. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236
Shapiro A, Castaman G, Cepo K, Tønder SM, Matsushita T, Poulsen LH, Young G, Zupancic-Šalek S, Jiménez Yuste V. Safety and Longer-term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Haemophilia. 2021;27(S2): 128. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236
(2021), Abstract. Haemophilia, 27: 18-181. https://doi.org/10.1111/hae.14236
Augustsson C, Ridell A, Fernandez-Bello I, Butta N, Kjalke M, Astermark J, Eichler H, Jimenez Yuste V, Chowdary P. ROTEM assay conditions sensitive to concizumab . Haemophilia. 2021;27(S2): https://doi.org/10.1111/hae.14236
Seremetis S, Cepo K, Rasmussen JS, Rose TH, Søren Tamer, Porstmann T, Haaning J. Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-fatal Thrombotic Events . Haemophilia. 2021;27(S2): 124. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236
Augustsson C, Ridell A, Fernandez-Bello I, Butta N, Kjalke M, Astermark J, Eichler H, Jimenez Yuste V, Chowdary P. ROTEM assay conditions sensitive to concizumab . Haemophilia. 2021;27(S2): https://doi.org/10.1111/hae.14236
Eichler H, Angchaisuksiri P, Astermark J, Benson G, Cepo K, Chowdary P, Hansen T, Kavakli K, Wheeler AP, Oldenburg J. Safety and longer-term efficacy of concizumab prophylaxis in patients with severe haemophilia A without inhibitors: Results from the extension part of the phase 2 explorer5 Trial . Haemophilia. 2021;27(S2): 95. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236
Witkop M, Wang M, Hernandez G, Recht M, Baumann K, Cooper DL. Impact of haemophilia on patients with mild-to-moderate disease: results from the P-FiQ and B-HERO-S studies . Haemophilia. 2021;27(Suppl. 1): 8-16. doi:https://doi.org/10.1111/hae.14251 https://onlinelibrary.wiley.com/doi/10.1111/hae.14251
Walsh C, Boggio L, Brown-Jones L, Miller R, Hawk S, Savage B, Hansen K, Molter D, Baumann K, Dunn S, Skinner M, Haugstad K, Johnson S, Davenport T, Bradbury M, Witkop M, Saad H, Cooper DL. Identified unmet needs and proposed solutions in mild-to-moderate haemophilia: a summary of opinions from a roundtable of haemophilia experts. Haemophilia. 2021;27(Suppl. 1): 25-32. doi:https://doi.org/10.1111/hae.14168 https://onlinelibrary.wiley.com/doi/10.1111/hae.14168
Rajpurkar M, Forsyth A, Manco-Johnson M. Current challenges for men and women with mild-to-moderate haemophilia. Haemophilia. 2021;27(Suppl. 1): 5-7. doi:https://doi.org/10.1111/hae.14193 https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.14193
Napolitano M, Olsen AA, Nøhr AM, Eichler H. Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C. J Blood Med. 2021;12:9-20
Benson G, Morton T, Thomas H, Lee XY . Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective. Clinicoecon Outcomes Res. 2021;13: 39-51. doi:https://doi.org/10.2147/CEOR.S280574
